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Abstract The lymphatic circulation is still a somewhat for-
gotten part of the circulatory system. Despite this, novel in-
sights in lymph angiogenesis in health and disease, application
of immune markers for lymphatic growth and differentiation
and also the introduction of new imaging techniques to visu-
alize the lymphatic circulation have improved our understand-
ing of lymphatic function in both health and disease, especial-
ly in the last decade. These achievements yield better under-
standing of the various manifestations of lymph oedemas and
malformations, and also the patterns of lymphovascular
spread of cancers. Immune markers that recognize lymphatic
endothelium antigens, such as podoplanin, LYVE-1 and Prox-
1, can be successfully applied in diagnostic pathology and
have revealed (at least partial) lymphatic differentiation in
many types of vascular lesions.
Keywords Lymph vessels . Vascular pathology .Metastasis .
Atherosclerosis . Angiogenesis . Vascular malformation .
Immunohistochemistry . Genetics . Circulation .
Lymphedema
Introduction
A most important discovery of anatomy and physiology was
Harvey’s description of the circulation of blood and a new
understanding of the function of the heart in 1628. However,
the full meaning of this ingenious research was first complete
with the recognition of the lymphatic vasculature in the mid-
dle of the 17th century. At last, the Galenic teaching could be
rejected. However, the lymphatic circulation is still a some-
what forgotten part of the circulatory system, since most re-
search interest is devoted to the blood vessels and related
diseases such as atherosclerosis and thrombosis.
Nevertheless, our understanding of its function and clinical
importance in both health and disease is improving, especially
in the last decade. The introduction of new imaging tech-
niques to visualize detailed anatomy and physiology of the
lymphatic circulation yields a better understanding of the var-
ious manifestations of oedemas and the patterns of
lymphovascular spread of cancers. New immuno markers rec-
ognize growth factors and differentiation antigens that are
specific for lymphatic endothelial cells which expands the
knowledge on lymphangiogenesis in chronic inflammatory
diseases and also in malignant tumours. Some of these im-
mune markers are now applied in diagnostic pathology and
reveal lymphatic differentiation in an increasing number of
vascular tumours or tumour-like conditions.
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Lymph vessels under normal conditions
Macroscopic anatomy and organization
The lymphatic vasculature is a drainage network that begins in
the interstitial spaces and ends in the great veins of the neck or
thorax. The lymphatic vessels can be divided into three differ-
ent types: initial lymphatics, pre-collectors and collecting lym-
phatics. The initial lymphatics are non-contracting vessels
composed of a single layer of lymphatic endothelial cells at-
tached to interstitial collagen fibres by anchoring filaments
and surrounded by a discontinuous basement membrane,
without pericytes [1]. Fluid entry is by absorption and depends
on a pressure gradient favouring fluid movement from inter-
stitium into the lymphatics. Further downstream, the lymph
reaches the pre-collectors, which contain valves and sparse
smooth muscle cell coverage. The pre-collectors connect the
absorbing initial lymphatics to the contractile collecting lym-
phatic vessels, which have smooth muscle cells (SMCs).
Unidirectional valves divide the collecting vessels into seg-
ments called lymphangions. These lymphangions contract
spontaneously and act as pumping units and are responsible
for propulsion of lymph (Fig. 1). The vessel wall is divided
into three layers, tunica intima, media and adventitia, albeit
less well organized than in blood vessels. Their smooth mus-
cle cell content increases proximally. The collecting lym-
phatics pump the lymph further centrally, which, after passing
through the regional lymph nodes, reaches the thoracic duct or
the right lymphatic trunk.
The human thoracic duct is comprised of SMCs arranged in
bundles with no distinct longitudinal or circumferential orien-
tation [2]. Ultrastructurally lymphatic SMCs resemble vascu-
lar SMCs with a complete basal lamina, caveolae in regular
alternation with membrane-associated dense bands, cytoplas-
mic dense bodies and thick (15 nm) as well as intermediate
(10 nm) and thin (5 nm) filaments [2]. Interstitial Cajal-like
cells have been reported in both human and sheep lymphatic
vessels based on morphology and immunohistochemistry [2,
3]. Whether these cells have the role as pacemaker cells, like
the interstitial cells of Cajal in the gastrointestinal tract, is not
yet known.
Physiological roles
The lymphatic system has three cardinal functions: (1) main-
tenance of interstitial fluid balance, (2) immune surveillance
and (3) absorption of fat. All ingested fat, except the small
amount of short fatty acids present in a normal diet, is taken
up by the intestinal lymphatics and transported to the venous
circulation. The lymphatic vessels play an important role in
host defence by carrying antigens and immune cells from the
tissues. It is therefore not surprising that lymphedema patients
have an increased risk and severity of skin infections.
Interstitial fluid balance
As blood passes through the capillaries, there is a con-
tinuous fluid filtration into the interstitial space. The
extravasation of fluid is dictated by the Starling forces
and accumulates to a total of 8 l of fluid during 24 h
[4]. The only way by which the fluid can be returned to
the blood circulation is via the lymphatic vasculature.
Traditionally, venous reabsorption was thought to play
the most important role, absorbing up to 90 % of the
fluid, but there is now comprehensive evidence that ve-
nous reabsorption is non-existent in most vascular beds
during steady state conditions [5]. Oedema occurs when
there is a mismatch between microvascular filtration and
lymphatic removal and can thus be caused by an in-
crease in filtration, reduced lymphatic removal or both.
Fig. 1 Intravital microscopy photographs showing a lymphatic vessel in
diastole (a) and systole (b). Thewhite arrowsmark the vessel wall and the
black arrow marks the valve. The corresponding diameter changes are
depicted in (c). Adapted with permission from Am J Physiol Heart Circ
Physiol 2007;293:H709-18
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Lymphatic failure or inadequacy is therefore present in
all chronic oedemas.
Lymph transport
Lymph transport is the result of a combination of intrinsic and
extrinsic factors. Arterial pulsation, skeletal muscle contrac-
tion and respiration are examples of extrinsic factors, which
cause transient tissue deformations leading to compression
and expansion of the initial lymphatics. Intrinsic spontaneous
contractions are generated in the lymphangions. Their con-
traction cycle is very similar to a cardiac ventricle. However,
the heart has two pumping chambers coupled in parallel,
whereas the lymphatic vessels have numerous pumping cham-
bers coupled in series. Systolic pressure generated by the
spontaneous contractions in humans can reach up to
100 mmHg, and several studies show averages of around
40–60 mmHg in arms and legs in humans, [6, 7]. The con-
tractions are influenced by many different stimuli: humoral,
neuronal, pressure, temperature and shear stress [8, 9]. Both
increases in preload and afterload lead to changes in contrac-
tility [10]. Similar to arteries, there is flow-mediated NO pro-
duction and myogenic constrictions as a response to increased
stretch [11, 12]. Lymphatic vessels show reactivity, either in-
hibitory or stimulatory to a vast panel of vasoactive substances
such as substance P, noradrenaline, histamine, endothelin and
prostaglandins [13–15]. Despite extensive evidence of a lym-
phatic innervation, most consistently described as sympathet-
ic, the exact role of the nerve supply remains unclear [16, 17].
Key points:
• Lymphatic vessels are widely distributed throughout the body. They can
be divided into absorbing, non-contracting initial lymphatics and con-
tractile collecting lymphatics.
• Lymph flow is not a passive process, but results from spontaneous
contractions generated in functional units called lymphangions
In vivo imaging of lymphatic vessels
Lymphoscintigraphy
Dysfunction of the lymphatics leads to oedema. Diagnosis of
the specific type of oedema is based on the history and clinical
findings, eventually supported by techniques available to as-
sess lymphatic function in a patient. Lymphoscintigraphy is
the current gold standard investigation to determine whether
limb swelling is the result of lymphatic dysfunction (Fig. 2)
[18].
Magnetic resonance lymphangiography
Magnetic resonance lymphangiography provides superior vi-
sualization of the lymphatic vessels, which allows better de-
scription of vessel morphology, but is inferior to scintigraphy
in the detection of lymph nodes [19].
Near infrared fluorescence imaging
Near infrared fluorescence imaging or indocyanine green lym-
phography is a relatively new technique used to visualize su-
perficial lymphatic vessels [20, 21]. The technique is based on
injection of a fluorescent dye that is absorbed by the lymphatic
vessels. The technique is used routinely to identify suitable
vessels for lymphatic-venous anastomosis surgery [22]. It is
furthermore used by some to stage lymphedema [23]. The
technique will probably play a key role in clinical practice
and research in the future.
Fig. 2 Lymphoscintigraphy of a healthy subject (a). Depots at the
injection sites on the feet and lymphatic vessels draining the injections
sites can be seen as well as the lymph nodes in the groin that the vessels
lead to. Lymphatic failure in a patient with Milroy’s disease (b). No
lympha t i c vesse l s o r up take in the gro in can be seen .
Lymphoscintigraphy of a patient with lymphedema distichiasis
syndrome (c). There is dermal reflux of lymph fluid in the lower legs.
No clear vessels can be seen and there is reduced uptake in the lymph
nodes in the groin
Key points:
• Lymphoscintigraphy is the gold standard for investigating the lymphatic
vasculature in humans. The techniques allow quantification of lymph
transport and visualization of the major lymphatic vessels.
• Magnetic resonance lymphangiography and near infrared fluorescence
imaging is emerging as new techniques due to superior spatial and
temporal resolution.
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Primary lymphedema
Primary lymphedema is caused by a failure of the develop-
ment of the lymphatic system (lymphangiogenesis) leading to
either structural or functional abnormalities that impair main-
tenance of interstitial fluid balance. Mutations within several
genes involved in the process of lymphatic development are
now known to cause different primary lymphedema pheno-
types. Primary lymphedema is not one disease, but the pre-
senting feature of several distinct clinical entities.
Previously, primary lymphedema was classified based on
age of onset: congenital, praecox (pubertal onset) and tarda
(onset after 35 years). The discovery of causal genes has
changed the diagnostic approach, which is now based on clin-
ical phenotyping and genotyping in addition to age of onset of
swelling (Fig. 3) [24]. Primary lymphedema can be divided
into five different categories: (1) lymphedema associated with
syndromic disorders (e.g. Turner or Noonan syndrome); (2)
localized or generalized lymphedema with systemic/visceral
lymphatic abnormalities; (3) lymphedema in association with
disturbed growth and/or cutaneous/vascular anomalies (e.g.
Proteus syndrome); (4) congenital lymphedema (e.g. Milroy
disease); (5) late-onset primary lymphedema. A number of
disease subtypes within each category have an associated
causal gene. Despite recent advances in genetics, mutations
in causal genes have only been detected in approximately one
third of all patients with primary lymphedema [25]. For an
overview over the causal genes and the resulting phenotype,
see Appendix.
The identification of the genetic cause of a patient’s
primary lymphedema provides a molecular diagnostic
test for a number of subtypes. Nine causal genes have
been discovered so far [26]. Patients and families bene-
fit hugely from the diagnosis as it allows the clinician
to confidently predict the clinical prognosis and offer
screening for family members. The identification of
new pathogenic genes will increase understanding of
the aetiopathogenesis of lymphatic disease. In time, this
may allow for the development of improved therapeutic
interventions. For example, gene therapy may become a
feasible treatment strategy for cases of primary
lymphedema.
Secondary lymphedema
Secondary lymphedema is the most common form of lymph-
edema. Globally, the parasite infection filariasis is the most
common cause with over 100 million people affected. In the
industrialized world, cancer-related lymphedema is the most
common cause, either as a direct consequence of the cancer or
the treatment.
Microscopic imaging of lymphatic vessels
and histopathology of lymphatics
Morphologically, it is difficult to distinguish lymphatic chan-
nels from venules or capillaries. In the era before development
of lymph endothelial-specific antibodies, a variety of tech-
niques was used to visualize lymphatic vessels, which includ-
ed injection techniques with India ink or Evans Blue, hydro-
gen peroxide techniques [27, 28] and the enzyme histochem-
ical detection of 5′nucleotidase [29].
Immunohistochemical markers for lymphatic
endothelium
Pan-endothelial markers such as CD31, CD34, von
Willebrand factor (vWF), lectins, thrombomodulin,
endoglin, and Fli-1 are expressed in all endothelial cells,
including lymphatic endothelium CD31(PECAM, plate-
let adhesion molecule) which is considered to be the
most sensitive and specific pan-endothelial marker but
is also reactive with platelets and subpopulations of T
lymphocytes [30, 31]. Lymphatic endothelial markers
are expressed in lymphatic endothelium, but not in
blood vessel endothelium. Table 1 summarizes the ex-
pression patterns of currently applied lymphendothelial-
specific antibodies, which can now be applied on
paraffin-embedded tissues.
Podoplanin is a mucin-type transmembrane glycopro-
tein originally described on rat kidney podocytes [32].
In the literature, it appears also under the names
AGGRUS, gp36, oncofetal antigen M2A and T1A-2
[33]. Apart from lymphatic endothelial cells, it is also
expressed by other cells types including tumour cells
[33]. D2-40 is the most common mouse monoclonal
antibody and NZ-1 the most commonly used rat mono-
clonal antibody against podoplanin [33, 34].
Prox-1 (homolog of the Drosophila melanogaster homeo-
box gene prospero) is a nuclear transcription factor, which
plays a crucial role in the development of the lymphatic
system. It is a master control gene introducing the expres-
sion of other lymphatic markers [35]. Immunoreactivity of
Key points:
• Primary lymphedema is caused by a failure of the development of the
lymphatic system whereas secondary lymphedema is the result of an
external stimulus, e.g. parasitic or cancer (metastasis or induced by
treatment).
• Advance in genetics have so far identified nine causal genes of primary
lymphedema and has helped refine the classification of primary
lymphedema, which now is based on clinical genotyping and
phenotyping.
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Prox-1 antibody is nuclear, which is in contrast to the other
lymphatic markers. Expression has been observed also in
lens, heart, liver, pancreas and nervous system [36]. In co-
lonic carcinomas, expression of Prox-1 in stem/progenitor
Fig. 3 Classification pathway for primary lymphedema. The pathway provides an overview over the different primary lymphedemas, clinical features
and causal genes. Fh= family history. Adapted with permission from Clinical Genetics 2013;84:303–314
Table 1 Expression of
immunohistochemical markers
for lymphatic endothelium along
the vascular bed
Lymphatic markers Podoplanin LYVE-1 Prox-1 VEGFR-3
Lymphatic vessels Capillary ++ ++ ++ ++
Collecting vessel ++ ++ + +/++
Blood vessels Artery - - - -
Capillary - - - +
Vein + - - -
Hepatic sinus + + - +
Embryonic development +/++ +/++ ++ +/++
Postnatal development ++ ++ ++ ++
− :no expression; +:weak expression; ++: strong expression; +/++: variable expression
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cells is responsible for autophagy-dependent survival of
metastases [37, 38].
LYVE-1 is an integral membrane glycoprotein also
known as lymphatic vessel endothelial hyaluronan receptor
1. It is an important component of extracellular matrix and
a key molecule in cell migration during inflammation,
wound healing and in tumorogenesis [39]. In addition to
the cytoplasm of lymphatic endothelium, it is expressed in
liver and spleen sinusoid endothelium and activated mac-
rophages [40].
Vascular endothelial growth factor receptor-3 (VEGFR-3,
also known as FLT4) is a membrane-anchored tyrosine kinase
b i n d i n g VEGF -C a n d VEGF -D i n v o l v e d i n
lymphangiogenesis [41]. VEGFR-3 was initially widely ap-
plied as a purely lymphatic marker, but later studies showed its
reactivity with blood vessel endothelium, myoepithelial cells
and cells of some non-endothelial tumours [42]. And also,
other markers such as neuropilin-2, FOXC2, CCL21, D6
and aquaporin-1 appear to be not fully specific for lymphatic
endothelium [43].
For studies on the (micro)vasculature in pathological con-
ditions, we recommend the use of a panel of three endothelial
antibodies, which consists of one pan-endothelial marker and
two different lymphatic endothelial-specific antibodies, in or-
der to avoid false positivity/negativity of staining results [44].
Key points
• CD31 is the most sensitive and specific pan-endothelial marker.
•Most important specific lymphatic endotheliummarkers are podoplanin
(D2-40), Prox-1, and LYVE-1.
• The use of the panel of one pan endothelial marker and two lymphatic
markers is recommended for proper identification of lymphatic vessels.
Lymphatic vessels: inflammation
Studies on lymph vessels in mouse models of inflammation
and inflamed human tissues have shown that acute inflamma-
tory reactions and chronic inflammatory diseases are accom-
panied by both the growth of new lymphatic vessels
(lymphangiogenesis) and the expansion of preexisting lym-
phatic vessels (lymphatic hyperplasia). These mechanisms oc-
cur not only in the inflamed tissues but also in draining lymph
nodes. Lymphangiogenesis, activation of lymph vessels and
enhanced lymphatic drainage may have modulating effects on
immune responses and the activity of the inflammatory pro-
cess which is now under intense investigation [45]. This has
been profoundly studied in arthritis, inflammatory bowel dis-
ease and dermatitis [46–49].
Lymphatic vessels: transplantation
Interestingly, chronic renal transplant rejection-associated
lymphatic vessel proliferation represents inflammation-
associated de novo lymphangiogenesis [50]. Also, chronic
cardiac allograft lymphangiogenesis is inflammation-driven
and the lymph vessels are important for migration of donor
and host antigen-presenting cells. There are indeed indications
that suppression of lymphangiogenesis improves graft surviv-
al, for example, through blocking of the dendritic cell chemo-
kine CCL21 in both heart and renal graft rejection [51, 52].
Lymphatic vessels: atherosclerosis, lipid metabolism,
obesity and hypertension
Lymphangiogenesis in intimal plaques and adjacent media has
been reported in atherosclerotic human coronary arteries,
where both the calcified and the cholesterol-rich types of
plaques are involved [44]. Plaque inflammation is an impor-
tant denominator in the formation of Bhigh risk plaques^
which are prone to thrombotic complications, and such an
increase in lymph vessels could play a role in further recruit-
ment of inflammatory cell into the plaque tissue. Moreover,
lymphatic vessels are involved in artery wall lipoprotein me-
tabolism and cholesterol plasma levels [53, 54]. Also, the
degenerative fibrocalcified heart valves of the elderly popula-
tion, which frequently display some low-grade inflammatory
activity with similar phenotypic features as in atherosclerosis,
appear to be prone to lymphatic growth. Aortic plaque-
associated lymphatic vessel growth has also been observed
in experimental mouse models of atherosclerosis [44].
Altogether, an inflammatory component in these diseases is
often associated with tissue instability and related cardiovas-
cular risk, which implies that such knowledge on lymphatic
vessels can be instrumental for assessment of a potential use of
antilymphangiogenic therapeutic strategies in atherosclerosis-
related diseases.
Lymphatic differentiation in tumours
and tumour-like lesions
Current classification
In practice (clinically and also pathologically) it can be diffi-
cult to determine whether a given vascular lesion is in fact a
true tumour, a developmental malformation or a reactive pro-
cess composed of either blood vessels, lymph vessels or both.
Consistent with this, there is variability in nomenclature and
sometimes misleading terminology in the literature, which
may hamper appropriate evaluation and management of pa-
tients. The classification of the International Society for the
Study of Vascular Anomalies (ISSVA), which stratifies the
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vascular anomalies into malformations and proliferative vas-
cular lesions, has recently been updated in order to attempt a
uniform state of the art and includes the main lymphatic tu-
mours and malformations, involvement in dysmorphic syn-
dromes and genetic backgrounds [55]. The online version is
also available at www.issva.org. A previous version of this
classification system has been validated recently in a large
referral centre for vascular anomalies [56]. It has proven to
be useful, also for clinical pathologists, albeit dependent on
the adequacy of clinical information, preoperative imaging
techniques and the use of immunohistochemistry for GLUT-
1 (infantile haemangiomas), specific lymphatic endothelium
antibodies, and the vascular smooth muscle antibody SMA-1(
vascular integrity and maturation).
Lymphatic malformations Lymphatic malformations (LMs)
are sponge-like collections of abnormal and cystically dilated
lymph vessels filled with lymph fluid. In the past, most lym-
phatic lesions were designated as lymphangiomas’, but in the
current classification, they now are labelled as ‘lymphatic
malformations’ because of the usually congenital nature,
slowly progressive growth over time and composition of mal-
formed dilated lymphatic vessels [55, 57]. Based on the size of
vessel lumen, LMs are classified as microcystic (previously
termed lymphangioma circumscriptum), macrocystic (previ-
ously termed cystic hygromas) or mixed subtypes [58]. They
can be located superficially or deep and occur (multi) focal or
diffuse. Sudden enlargement may occur during infection or
spontaneous bleeding within the cysts. Many lesions are con-
genital, although not always visible at birth, but small lesions
may develop also in response to trauma or infection.
Lymphangiogenic growth factors, such as VEGF-C and
VEGFR-3, are upregulated in LMs, but the precise role of
these factors in their development is not clear [59]. In histo-
pathology, an LM reveals a convolute of dilated lymph vessels
with incomplete medial layers of one to multilayered smooth
muscle cells and can be associated with nodular lymphoid
tissue (Fig. 4a–c). Endothelial cell lining is flat but obtains a
hobnail-like appearance, in cases with trauma, haemorrhage
or chronic inflammation (Fig. 1). Endothelium stains positive-
ly with several lymphatic specific antibodies [60], but staining
intensity can be markedly reduced in the flat endothelium of
Fig. 4 Lymphatic malformation with intralesional formation of lymph
follicles (a–c); Haematoxylin and eosin stain (HE) (a); anti-CD31 immu-
nostain (b); anti-D2-40 immunostain of endothelium (c); macrocystic
lymphatic malformation (d–e): HE (d); CD31, low intensity to absent
immunostaining with D2-40 antibody of endothelial cells at cystic struc-
tures (e) (compared with D2-140 immunostain in (f)); Traumatic changes
and haemorrhage in LM (g–h), with hobnail-type endothelium in (h). D2-
40 immunostaining of microvessels (i)
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cystically dilated lymph channels (Fig. 4d–k). Traumatic
changes in lymphatic malformations frequently cause haem-
orrhage and thrombosis , especial ly in combined
lymphaticovenous malformations. Therefore, presence of
erythrocytes in vessel lumina does not rule out a diagnosis
of a lymphatic lesion. Additional hamartomatous tissue com-
ponents such as fat, nerve bundles or of reactivemicrovascular
proliferations, which are frequently found in congenital
malformations of blood vessels, are not a feature of pure lym-
phatic malformations [61, 62].
Vascular tumours with lymphatic differentiation
The use of monoclonal antibodies specific for lymphatic en-
dothelium has revealed lymphatic endothelial differentiation,
at least to some extent, in a still increasing list of vascular
tumours that were initially considered to be composed of
blood vessels only (Table 2). However, in many of these le-
sions, the patterns of immunostaining vary when different
lymphatic antibodies are applied (see for example Fig. 5).
Therefore, it is recommended to use two different lymphatic
antibodies; salient examples of such ‘newly’ described lym-
phatic lesions are as follows:
1. Spindle cell haemangioma. First reported in 1986 as low-
g r a d e ma l i g n a n t a n d t e rm ed s p i n d l e c e l l
hemangioendotheliomas [63]. It is now considered as a
benign type of lesion with clinical and biological features
more reminiscent of congenital vascular malformations.
A recent study of 12 cases of spindle cell haemangiomas
showed a positive endothelial lining with coexpression of
pan-endothelial and lymphatic antibodies, suggesting its
lymphatic origin [64].
2. Multiple lymphangioendotheliomatosis. An extremely
rare disease in infancy associated with thrombocytopenia
[65]. Patients present with hundreds of congenital vascu-
lar lesions in the skin, which have the characteristics of
both blood vascular and lymphatic vessels (Fig. 5).
Similar lesions involve the gastrointestinal (GI) tract caus-
ing severe GI tract bleeding.
3. Kaposiform hemangioendothelioma (KHE) of childhood.
This is a vascular tumour with a locally aggressive behav-
iour and often complicated by severe coagulopathies (in
the most serious form, the Kasabach-Merritt syndrome)
[66]. However, these coagulation abnormalities are not
unique for KHE but have been noticed also in other vas-
cular tumours and malformations [56]. Spindle cells of
this tumour coexpress blood and lymphovascular markers
[67].
4. Kaposi sarcomas (KS). Also coexpress blood vascular
and lymphatic markers in all the histopathological vari-
ants. These markers are useful in the recognition of KS,
since there is a variation in morphology of the lesions
varying from scant multicentric, small dilated
microvessels to solid spindle cell proliferations; others
present as polypoid tumour masses mimicking pyogenic
granuloma or even closely resembling haemangiomas.
Recent studies have shown that the KS herpes virus can
Table 2 Tumours and tumour-
like lesions with at least partial
lymphatic differentiation
Name Biological behavior according to ISSVAa 2015 [55]
Primary lymphoedema/
lymphatic malformation
Congenital malformation. Isolated or in combination with other vascular or
nonvascular malformations or genetic syndromes
Tufted angioma Benign tumor of skin. Partial lymphatic differentiationb
Spindle cell angioma Provisionally unclassified. Probably vascular malformation with partial
lymphatic differentiation
Verrucous angioma Provisionally unclassified; probably congenital malformation with partial
lymphatic
Angiokeratoma Provisionally unclassified vascular anomaly. Partial lymphatic
differentiation
dMLT/CATc Provisionally unclassified lesion.
Kaposiform
hemangioendothelioma
Locally aggressive tumor. Extends into deep tissues; resembles tufted
angioma
PILAd Borderline malignant tumour
Kaposi sarcoma Borderline malignant tumour
Lymphangiosarcoma Malignant. Variable expression patterns with lymphatic markers
Kaposiform lymphangiomatosis Provisionally unclassified vascular lesion
a International Society for the Study of Vascular Anomalies
b Partially lymphatic indicates: composed of blood vessels and lymph vessels
c Diffuse multiple lymphangioendotheliomatosis
d Papillary intralymphatic angioendothelioma (Dabska tumour)
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infect endothelial cells of blood vessels and reprogram the
neoplastic HHV8-infected endothelial cells to lymphatic
endothelium. The tumour cells show induction of lym-
phatic lineage-specific genes, including Prox1 and down-
regulation of blood vascular genes [68, 69].
5. Angiosarcomas. Application of lymph endothelial specif-
ic antibodies has revealed at least partial lymphatic differ-
entiation in a large subset of lesions that were traditionally
considered to be true hemangiosarcomas (both the solitary
and the radiation induced types of tumours). In a recent
study of 49 angiosarcomas by Mankey et al. [70], more
than hal f of the number of tumours showed
immunopositivity with at least two out of three applied
lymphatic antibodies (D2-40, Prox 1, LYVE-1).
Especially, tumours with intratumoral aggregates of lym-
phoid tissue and prominent hobnail appearance of
endothelium showed broadest immunoreactivity with
these markers. This implies that at least histopathological-
ly, they should be defined as lymphangiosarcomas.
Lymphovascular invasion: patterns and diagnosis
The importance of vascular invasion in tumour biology
was established over 100 years ago. In his classic text-
book, Willis summarized the early work and described
the patterns of tumour spread in autopsies on patients
with a variety of disseminated cancers [71]. From the
numerous recent studies on lymphatic and blood vessel
invasion (LBVI) in surgically resected tumours, we have
summarized reports which emphasize the importance of
accurate detection of vascular invasion (Table 3). Many
of these reports indicate no clear distinction between
lymphatic and blood vessel invasion or do not focus
on lymphatic vessels in depth. In everyday practice,
the detection of lymphatic invasion (LI) alone is espe-
cially important in breast carcinoma and malignant mel-
anoma in particular because it may influence on patient
management or the choice of adjuvant chemotherapy
[78, 80, 81].
Fig. 5 Multiple lymphangioendotheliomatosis. Skin surface with
subepidermal dilated thin-walled vessels (HE) (a); deep-seated atypical
vessels in subcutis, partially filled with erythrocytes (HE) (b); CD31
immunostain of atypical microvessels (c); absent D2-40 immunostaining
(d); focal LYVE-1 immunostaining of microvessels (e)
Key points
• Many lesions that were previously designated as ‘lymphangiomas’ are
in fact lymphatic malformations, being mostly congenital in nature
• Specific lymphatic endothelium antibodies identify (partial) lymphatic
differentiation in a still increasing number of vascular tumours
• Occurrence of blood-filled spaces, haemorrhages or hobnail appearance
of endothelium does not rule out the diagnosis of a lymphatic lesion
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Detection of lymphovascular invasion in surgical
resections
1. Breast
LBVI is underdetected in breast carcinoma, probably
in as many as a fifth of cases. Blood vessel and lymphatic
endothelial markers are helpful in detection of LBVI both
within and at the edge of tumours. Invasion in vessels at
the advancing tumour edge is especially important [81]. In
a recent review of more than 30 reports, Gujam et al.
found that blood or lymphatic vessel invasion was detect-
ed in 24 % of cases on H&E rising to 35 % with immu-
nohistochemistry [78]. Although the exact prognostic sig-
nificance of vascular invasion is uncertain, its presence or
absence may influence the type of chemotherapy that is
used. The review emphasizes that the detection of LI is
especially important in operable breast carcinomas with-
out lymph node spread. However, some studies indicate
LBVI in node-positive breast carcinoma may be
prognostically valuable.
2 Oesophageal and gastric carcinomas
The incidence of oesophageal and gastric carcinomas is
increasing in many countries and the 5-year survival is
persistently low. In some studies of oesophageal carcino-
ma, venous invasion was found to reduce both disease-free
survival and cancer-specific survival [82]. Recognition of
any type of vascular invasion in oesophageal carcinoma is
now a requirement and distinction between lymphatic and
venous may be relevant [83].
In earlier studies, gastric cancer LBVI was indepen-
dently related to survival and cancer recurrence [84] re-
gardless of tumour stage or size [85]. LI is a common
feature in gastric cancer but despite early suggestions of
lymphatic invasion alone playing an independent prognos-
tic role [86], this hypothesis requires further confirmation.
3 Colorectal cancer
The latest colorectal cancer dataset of the Royal College
of Pathologists of Great Britain and Ireland incorporates
assessment of intramural and extramural vascular invasion
and the distinction of lymphatic and venous involvement
in colorectal carcinoma [87]. Lymphatic invasion was sug-
gested as an adverse factor for survival more than 20 years
ago [88] but the current prognostic emphasis is put on
extramural venous invasion. It is especially important to
identify LBVI in Dukes B cancers where its status may
guide decisions on adjuvant therapy [89].
Specialists in GI pathology report LBVI more frequent-
ly than do general pathologists (30 vs 9 %) but even they
increase their rate of detection when elastin stains are used
(Table 1) [77]. A recent study by Kojima et al. showed
marked improvement of detection of LBVI including LI
after agreement of set microscopic criteria after a series of
questionnaires and consensus meetings between patholo-
gists (Delphi method). Two features reaching the highest
kappa value in the study were either a rim of elastin or D2-
40 marking cells covering more than 50 % circumference
of a tumour cluster [90].
4 Malignant melanoma
There is currently well-documented preferential LI in
cutaneous malignant melanoma. In the recent work, Rose
et al. examined 246 cases of malignant melanoma and
showed D2-40 marker staining increased detection rate
of LI sixfold compared with routine H&E. After statistical
evaluation, LI remained an independent prognostic factor
for adverse patient prognosis [80]. In a UK multicentre
study, Storr et al. showed over a quarter of examined cases
were positive for LI compared with only 4 % of invaded
blood vessels. LI correlated with mitotic rate, ulceration
and Breslow thickness but statistically failed to reach in-
dependent prognostic significance [76].
Fig. 6 Detail of tumour (melanoma) with lymphovascular invasion; CD31 immunostain showing immunoreactivity of endothelium in all microvessels
(a); D2-40 immunostain showing immunoreactivity of endothelium with intravascular tumour deposit (b)
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Techniques for detection of lymphatic and venous invasion
The studies discussed above and summarized in Table 3 em-
phasize the importance of LBVI and stress that it is often
underdiagnosed. Three different approaches can be used to
increase the accurate detection of invasion.
& Appropriate sampling of tumours and adjacent tissues
Few studies have specifically addressed dissection
techniques for the enhanced detection of LBVI. The con-
vention that malignant tumours should be sampled in three
blocks is outdated and we advocate a minimum of five.
Sternberg and colleagues dissected blocks perpendicular
and tangential to tumours, blocks taken across the mesen-
tery and around major blood vessels [91]. The authors
found that LBVI was most often detected in perpendicular
blocks but in some cases, it was only identified in the
tangential blocks. Further studies of dissection techniques
and the number of blocks that should be sampled would be
valuable.
& BWhat to look for^—recognition of the particular histo-
logical features of vascular invasion
The multicentre Canadian study of Kirsch et al. de-
scribed two important histological signs that suggest
LBVI in colorectal carcinoma, although no distinction
was made between lymphatic and blood vessels. Veins
and arteries are closely related to each other but this is
especially true in the bowel wall. The so-called protruding
tongue sign is a rounded protrusion of carcinoma extend-
ing towards the extramural space at the tumour edge. This
suggests venous invasion, especially if the deposit is close
to a small artery. In the ‘lone artery’ or ‘orphan arteriole’
sign, an often elongated tumour deposit is seen next to a
normal extramural artery. This, in fact, is an obliterated
vein twinned with the artery [77]. Whether this also ap-
plies to lymph vessels is not known.
& Routine use of special stains, especially elastic tissue
stains and vascular immunohistochemistry.
Small- and medium-sized lymphatics contain a net-
work of elastic tissue although less in abundance than in
veins. In contrast to arteries, this is not arranged as distinct
internal and external lamellae but as an irregular network.
Small lymphatic invasion can be identified with
immunomarkers but larger vessel invasion might be indis-
tinguishable from venous as the endothelium is obliterated
by most carcinomas. Elastin can form tumour within nests
of malignant cells andmust not bemistaken as evidence of
vascular invasion. In this context, Kojima et al. suggested
that venous invasion should only be diagnosed when a
tumour deposit has 50 % of its circumference surrounded
by elastin or D2-40 [90]. Remnants of vascular media of
larger veins or lymph vessels can sometimes be visualized
adjacent to tumour deposits with the use of smoothmuscle
actin immunostaining. Figure 6 displays intratumoral in-
vasion of small vessels by immunostaining for CD31 and
D2-40.
Representative studies that emphasize use of LVI in surgi-
cal resections are listed in Table 3. Multiple studies of gastro-
oesophageal and colonic carcinomas have shown that intra-
mural and extramural LBVI is easily missed. Routine and
inexpensive elastic tissue stains increase the diagnostic accu-
racy of both specialist and non-specialist pathologists. We
suggest that they should be used routinely. In most reports,
no clear distinction is made between lymphatic and blood
vessel invasion. However, for certain tumours, especially mel-
anomas, this appears to be relevant as shown in recent studies
where immunohistochemistry with specific endothelial anti-
bodies was applied to discriminate between lymphatic and
blood microvasculature. These techniques at least increase
the detection of venous and lymphatic invasion in mammary
carcinoma and in melanoma. They should be used in selected
cases, especially node-negative operable tumours.
Key points
• LI detection in breast carcinomas is especially important in patients with
operable breast cancer without lymph node involvement.
• Defined criteria of vascular invasion need to be used alongside special
stains to detect vascular invasion in colorectal carcinoma.
• Vascular antibodies, particularly the lymphatic marker D2-40, improve
detection of LI in malignant melanoma.
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